Shinhan Venture Investment

Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF) and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development.

Contents Technologies is a leading content IP-based company that develops technology solutions for artists and creators. Specializing in intellectual property and marketing services, it utilizes various content value chains to enhance the commercial opportunities for artists and improve the value of intellectual properties. The company is dedicated to innovation and entrepreneurship, enabling clients to concentrate on their core activities while expanding their businesses. By providing advanced technology and support, Contents Technologies aims to empower creators and facilitate the growth of the content industry in Asia and beyond.

Ideahub Inc. is a professional services company specializing in patent monetization and intellectual property (IP) licensing and commercialization. Founded in 2016 and headquartered in Seoul, South Korea, Ideahub offers an IP licensing platform designed to help clients monetize their IP portfolios. The company provides a range of services, including licensing support and potential revenue analysis, focusing on various sectors such as the Internet of Things (IoT), industrial automation, telecommunications, audio technology, augmented and virtual reality, and video entertainment.

Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF) and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development.

HYBE is a music-based entertainment lifestyle platform that specializes in various aspects of the music industry. The company is involved in music production, publishing, and the development of new artists. It also focuses on artist management and offers a comprehensive range of services through its 360° business model. Additionally, HYBE engages in intellectual property (IP) business and operates platforms that enhance its offerings in the entertainment sector. Through these diverse activities, HYBE aims to create a holistic ecosystem that supports artists and connects them with fans globally.